SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-280729
Filing Date
2021-09-23
Accepted
2021-09-23 16:30:59
Documents
16
Period of Report
2021-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d208955d8k.htm   iXBRL 8-K 34149
2 EX-1.1 d208955dex11.htm EX-1.1 208181
3 EX-3.1 d208955dex31.htm EX-3.1 63607
4 EX-5.1 d208955dex51.htm EX-5.1 7786
8 GRAPHIC g208955g92y61.jpg GRAPHIC 2921
  Complete submission text file 0001193125-21-280729.txt   527792

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20210920.xsd EX-101.SCH 2916
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20210920_lab.xml EX-101.LAB 19659
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20210920_pre.xml EX-101.PRE 12331
9 EXTRACTED XBRL INSTANCE DOCUMENT d208955d8k_htm.xml XML 3781
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 211272855
SIC: 8071 Services-Medical Laboratories